Pharmas acquiring exclusive rights to gain access to new markets and innovation will be a strong trend in 2017

28 March 2017

In an expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, discusses why acquiring exclusive rights will continue to be a key driver for pharma mergers and acquisitions (M&A) in 2017 by providing companies with cheaper and faster access to new innovation, markets and geographies, while also enabling pharmas to unlock significant synergies allowing them to remain competitive.

Forthcoming European elections, Trump’s plans to re-set key global trading relationships and political uncertainty in the UK continue to unsettle investor sentiment. While some businesses have paused their M&A plans due to this flux, the start of 2017 has been marked by healthy levels of M&A in the pharma sector and we can expect investor pressure on companies to increase revenue growth to drive the search for strategic deals that will deliver value and opportunities for expansion.

Recent deals announced saw big and small pharma companies purchasing exclusive rights to blockbuster products rather than pursuing outright acquisitions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK